Clozapine Rechallenge After Myocarditis
The one drug that ever controlled his psychosis nearly cost him his life a different way. With no other effective option ever found, rechallenge is a real question, not a reckless one.
T.B., a 29-year-old man, was two years into a computer science degree when his first psychotic episode forced him to withdraw, and the six years since have been defined, his family says, by watching him try repeatedly to get back to that unfinished degree and fail each time as his illness resisted every treatment tried. He spent those six years cycling through five different antipsychotics with only partial, unstable control of severe psychotic symptoms before clozapine was finally tried and, within its first weeks, produced the only real remission he has had since his diagnosis — enough clarity to return to part-time community college classes and reconnect with his family, before the trial itself was cut short in its fifth week.
In week five of that trial, he developed fever, chest pain, and elevated troponin and CRP, and was diagnosed with clozapine-induced myocarditis, confirmed by cardiology workup; clozapine was stopped immediately and he recovered fully over the following weeks with no lasting cardiac impairment. His parents describe that recovery with real relief, but also describe the two years since as a return to exactly the instability clozapine had briefly interrupted.
In the two years since, every other antipsychotic tried — including a second attempt at combinations that had failed before clozapine — has produced only the same partial, unstable control that defined his pre-clozapine course. His family describes watching him lose, over those two years, essentially everything clozapine had given back to him. Rechallenge after clozapine-induced myocarditis is not standard practice and carries a real risk of recurrence, described in the literature as substantial though not universal; it is also not absolutely contraindicated, and case reports describe successful rechallenge, typically with a much slower titration and closer cardiac monitoring than the original trial used. There is no dataset large enough to give T.B. a reliable individual probability either way.
Rechallenge or continue searching for alternatives
A prior clozapine myocarditis is a real signal, not noise. Richardson and colleagues' 2021 systematic review of published rechallenge cases found recurrence in a little over a third of attempts, and at least one of those recurrences was fatal. I'm not saying no — but I want a monitoring protocol that would catch this far earlier than his first episode was caught, given how quickly myocarditis can progress once it starts.
That number is real, and I'm not going to argue it away — a fatal outcome in that literature means this isn't a decision to make lightly, and I don't intend to. But I'd weigh it differently than a purely cardiac read would, and frame it as T.B.'s decision to make, informed rather than made for him.
You called it "a real signal, not noise" — I'd say two years of documented functional decline on every alternative is also a real signal, not background noise we can discount just because it isn't cardiac. Five weeks of clozapine did something nothing else in six years has done, and two years of alternatives have now confirmed nothing else does it again. That belongs in the same calculation as the recurrence rate you're citing, not treated as a softer, secondary consideration.
If we go forward — and I think the two of you have actually converged on that, not just talked past each other — the titration needs to be genuinely different from the first attempt. The rechallenge literature is fairly consistent on this specific point: slower titration and closer biomarker monitoring, not a faster decision, is what separates the successful cases from the recurrences. A rechallenge that repeats the original five-week pace isn't a real mitigation of the risk you named — it's the same trial again with different paperwork.
Agreed, after T.B. himself weighed in directly: proceed with a cardiology-supervised clozapine rechallenge, using a substantially slower titration than the original trial and scheduled biomarker monitoring from the first dose.
Clozapine stopped immediately; this becomes a second confirmed episode, closing the door on any future rechallenge attempt.
Titration continues toward the dose that produced his prior remission, with monitoring intervals gradually extended.